📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 15:34
690 analysed today
690
Today
133,579
All-time analysed
40,122
Positive
6,284
Negative
79,354
Neutral
7,751
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
8 announcements match the current filters (relevance ≥ 5).
Kwality Pharma targets Rs 700+ Cr revenue in FY27 and Rs 1500 Cr by FY30
Kwality Pharmaceuticals has provided aggressive growth guidance, targeting over Rs 700 Cr revenue in FY27, a ~40% increase from FY26. Management expects EBITDA margins to improve to 26-27% (up from 23.5% TTM) as the product mix shifts toward Oncology, which is targeted to reach 25-30% of sales by Q4 FY27. A new hormone plant (Unit 6) is scheduled to commence in November 2026, and the company has set a long-term revenue milestone of Rs 1500 Cr by FY30. Clinical trials for its first biosimilar, Erythropoietin, are expected to begin in late 2026 with commercialization by late 2027.
Confidence: HIGH
What changedManagement has formalized a multi-year growth roadmap, upgrading margin expectations and providing specific timelines for new facility commissions and biosimilar launches.
Why it mattersThe transition from simple generics to complex injectables, oncology, and biosimilars is a structural shift aimed at higher margins and reduced competition in regulated markets like LATAM and Europe.
FY27 Revenue Guidance: Rs 700+ CrFY30 Revenue Target: Rs 1500 CrEBITDA Margin Guidance: 26% to 27%Hormone Plant Start Date: November 2026Oncology Revenue Mix Target: 25% to 30%
📅 Short termThe stock may react positively to the clear growth visibility and margin expansion guidance provided for the current and upcoming fiscal years.
📈 Long termIf the company achieves its Rs 1500 Cr target by FY30 through complex products, it represents a significant structural re-rating from a small-cap generic player to a specialized pharma entity.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in clinical trials for biosimilars
- Regulatory approval timelines for oncology registrations in regulated markets
- Geographic concentration in LATAM (35% target)
Key Highlights
FY27 revenue guidance set at Rs 700+ Cr, representing 39% growth over FY26 revenue of Rs 503 Cr
EBITDA margin guidance of 26-27% exceeds the current TTM operating margin of 23.5%
Unit 6 Hormone plant to commence operations by November 2026
Long-term FY30 revenue target of Rs 1500 Cr, implying a 3x scale-up from FY26 levels
Oncology segment targeted to contribute 25-30% of total revenue by Q4 FY27
👀 What to Watch
Watch for the successful commissioning of the Hormone plant in November 2026 and the initiation of Erythropoietin clinical trials in Q3 FY27 as key execution milestones.
Kwality Pharma guides for Rs 700 Cr+ FY27 revenue and Rs 1500 Cr by FY30
Kwality Pharmaceuticals has issued aggressive growth guidance, targeting over Rs 700 Cr revenue in FY27, representing a ~40% increase over TTM revenue of Rs 502 Cr. Management expects EBITDA margins to expand to 26-27% (vs TTM OPM of 23.5%) driven by a shift toward high-margin oncology and hormone products. The company's sixth unit (Hormone plant) is scheduled to commence in November 2026, while clinical trials for its first biosimilar (Erythropoietin) are set for late 2026. Long-term targets aim for Rs 1500 Cr revenue by FY30, with a significant contribution expected from European and LATAM markets.
Confidence: HIGH
What changedManagement has provided a concrete roadmap for FY27 and FY30, including specific timelines for new facility commissioning and biosimilar clinical trials.
Why it mattersThe transition from simple generics to complex injectables, hormones, and biosimilars is a structural shift intended to improve margins and scale the business 3x by 2030.
FY27 Revenue Guidance: Rs 700 Cr+FY30 Revenue Target: Rs 1500 CrTarget EBITDA Margin: 26% to 27%Hormone Plant Commencement: November 2026FY27 Guide vs TTM Revenue: ~139%
📅 Short termPositive sentiment is expected as the market reacts to the strong revenue and margin guidance, alongside the clear timeline for the new hormone facility.
📈 Long termIf the company successfully executes its biosimilar and oncology strategy, it could structurally re-rate as it moves toward the Rs 1500 Cr revenue mark by FY30.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in clinical trials for biosimilars
- Potential delays in high-regulated market registrations (EU/Mexico)
- High current P/E of 48.2
Key Highlights
FY27 revenue guidance of Rs 700 Cr+ implies ~40% growth over TTM revenue of Rs 502 Cr
EBITDA margin guidance raised to 26-27% from current TTM levels of 23.5%
Unit 6 (Hormone plant) to commence operations by November 2026
Secured 60-70 new product registrations in the last three quarters, each contributing Rs 12-16 Cr annually
Long-term FY30 revenue target set at Rs 1500 Cr, nearly 3x current TTM revenue
👀 What to Watch
Monitor the timely commencement of the Hormone plant in November 2026 and the start of Erythropoietin clinical trials in December 2026 as key execution milestones. Investors should also track the oncology revenue mix, which management aims to scale to 25-30% by Q4 FY27.
Kwality Pharma raises FY27 revenue guidance to Rs 700+ Cr; Q1 PAT jumps 119% YoY
Kwality Pharmaceuticals reported a robust Q1FY27 with revenue growing 45.7% YoY to Rs 162.4 Cr and PAT surging 119.3% YoY to Rs 25.7 Cr. Management has upgraded its FY27 revenue guidance to Rs 700+ Cr (up from Rs 650 Cr), implying a 39%+ growth over FY26. Profitability outlook is also raised with EBITDA margins targeted at 27-28%+, driven by a shift toward high-margin oncology, biologics, and complex injectables. The company is on track to complete its new hormone facility (Unit 6) by Q3CY26.
Confidence: HIGH
What changedThe company has officially upgraded its full-year FY27 financial guidance across revenue, EBITDA, and PAT metrics following a strong Q1 performance.
Why it mattersThe guidance upgrade and margin expansion target (to 27-28%) signal a successful transition from low-margin generics to high-entry-barrier complex formulations and biologics.
Q1FY27 Revenue: Rs 162.4 CrQ1FY27 PAT Growth (YoY): 119.3%FY27 Revenue Guidance: Rs 700+ CrFY27 PAT Guidance: Rs 109+ CrTarget EBITDA Margin: 27-28%+Cash Conversion Cycle: 161 days
📅 Short termThe stock is likely to react positively to the substantial guidance upgrade and the doubling of quarterly profits.
📈 Long termStructural growth is supported by a pipeline of 40+ bio-equivalence programs and a shift toward specialized segments like Oncology and Biologics which should sustain higher valuations.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory risks associated with EU-GMP audits
- Execution risk in the commercialization of new biologics
- Potential geographic drag from the Africa subsidiary
Key Highlights
Q1FY27 Revenue increased 45.7% YoY to Rs 162.4 Cr, representing ~32% of TTM revenue in a single quarter
FY27 Revenue guidance raised to Rs 700+ Cr from previous Rs 650 Cr, targeting 39% YoY growth
PAT guidance for FY27 raised to Rs 109+ Cr, a significant jump from FY26 actual PAT of Rs 67 Cr
Cash conversion cycle improved drastically to 161 days in FY26 from 297 days in FY23
Unit 6 (Hormones) construction is underway with expected completion by Q3CY26
👀 What to Watch
Watch for the successful commercialization of the first biologic, Erythropoietin, in H1FY28 and the outcome of upcoming EU-GMP audits which are critical for regulated market entry.
119% YoY PAT Growth in Q1 FY27; Management Raises FY27 Revenue Guidance to ₹700+ Cr
Kwality Pharmaceuticals reported a strong start to FY27, with consolidated revenue growing 46% YoY to ₹162.35 Cr and PAT surging 119% YoY to ₹25.62 Cr. EBITDA margins expanded to 25.3% from 21.9% YoY, reflecting a shift toward higher-margin complex injectables and biologics. Management has significantly raised its FY27 guidance, now targeting revenue of ₹700+ Cr (up from ₹503 Cr in FY26) and PAT of ₹109+ Cr. The company also completed 13 Bioequivalence studies and secured 15+ new product registrations globally during the quarter.
Confidence: HIGH
What changedThe company has upgraded its annual financial outlook and demonstrated significant margin expansion through a shift into niche, high-barrier product segments.
Why it mattersThe sharp increase in profitability and aggressive guidance suggest that the company's transition from simple generics to complex injectables and biologics is gaining commercial traction.
Q1 Revenue Growth (YoY): 46%Q1 PAT Growth (YoY): 119%FY27 Revenue Guidance: ₹700+ CrEBITDA Margin (Q1): 25.3%Hormone Facility Completion Date: November 2026Q1 EPS: ₹24.69
📅 Short termThe stock is likely to react positively to the substantial earnings beat and the upward revision of full-year guidance.
📈 Long termStructural expansion into biologics and complex injectables, supported by global regulatory approvals, positions the company for higher-margin growth over the next 2-3 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in clinical trials for biologics
- Regulatory compliance risks for high-regulated markets (EU-GMP)
- Potential operational drag from the African subsidiary
Key Highlights
Consolidated revenue increased 46% YoY to ₹162.35 Cr for the quarter ended June 30, 2026.
Net Profit (PAT) surged 119% YoY to ₹25.62 Cr, with PAT margins improving from 11% to 16%.
Management raised FY27 revenue guidance to ₹700+ Cr, representing a ~39% growth over FY26.
Completed 13 Bioequivalence (BE) studies as part of a 40-molecule program across General, Beta Lactam, and Oncology units.
Hormone manufacturing facility construction is on track for completion by November 2026.
👀 What to Watch
Monitor the timely completion of the Hormone facility in November 2026 and the clinical trial progress of biologics like Erythropoietin, which are key to achieving the upgraded FY27 guidance.
119% PAT Growth in Q1 FY27; Management Raises FY27 Revenue Guidance to ₹700+ Cr
Kwality Pharmaceuticals reported a strong start to FY27 with consolidated revenue growing 46% YoY to ₹162.35 cr and PAT surging 119% YoY to ₹25.62 cr. The company achieved significant margin expansion, with PAT margins rising from 11% to 16% YoY, driven by a shift toward high-barrier products. Management has notably raised its FY27 revenue guidance to ₹700+ cr, a ~39% increase over FY26 revenue of ₹503 cr. Operational progress remains robust with 13 Bioequivalence studies completed and a new hormone facility scheduled for completion by November 2026.
Confidence: HIGH
What changedThe company reported a massive earnings beat and significantly upgraded its full-year FY27 guidance across revenue, EBITDA, and PAT metrics.
Why it mattersThe results validate the company's strategic shift from simple generics to high-margin complex injectables and biologics, reflected in the 400+ bps expansion of EBITDA margins to 25.3%.
Q1 FY27 Revenue Growth (YoY): 46%Q1 FY27 PAT Growth (YoY): 119%FY27 Revenue Guidance: ₹700+ crEBITDA Margin: 25.3%Hormone Facility Completion Date: November 2026Guidance vs TTM Revenue: ~39% growth
📅 Short termThe stock is likely to react positively to the sharp earnings growth and the substantial upward revision in management guidance.
📈 Long termThe transition into biologics (Pembrolizumab) and regulated markets like the EU represents a structural shift that could sustain high growth rates if regulatory approvals are secured.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk in clinical trials for biologics
- Potential geographic drag from the Africa subsidiary which had zero revenue in FY25
- High dependence on regulatory audits (EU-GMP)
Key Highlights
Consolidated revenue increased 46% YoY to ₹162.35 cr in Q1 FY27 compared to ₹111.48 cr in Q1 FY26.
Net profit (PAT) surged 119% YoY to ₹25.62 cr, with EPS rising to ₹24.69 from ₹11.49.
Management raised FY27 revenue guidance to ₹700+ cr, significantly higher than the previous ₹500 cr target.
Completed 13 Bioequivalence (BE) studies during the quarter as part of a 40-molecule program.
Hormone manufacturing facility construction is on track for completion by November 2026.
👀 What to Watch
Investors should monitor the timely completion of the Hormone facility in November 2026 and the progress of biologics candidates like Erythropoietin through clinical trials, which are key to the upgraded guidance.
Kwality Pharma targets ₹700 Cr+ FY27 revenue; FY26 PAT grows 69% to ₹67.3 Cr
Kwality Pharmaceuticals successfully met its three-year target of doubling revenue, reporting ₹503 Cr for FY26, a 36% YoY increase. Profitability outpaced revenue growth, with PAT surging 69% to ₹67.3 Cr and EBITDA margins expanding 200 bps to 24%. Management has upgraded its FY27 revenue guidance to over ₹700 Cr (from ₹650 Cr) and set a long-term goal of ₹1,000 Cr by FY29. The company is pivoting toward high-margin biologics and complex injectables, with its first biologic launch planned for CY2027.
Confidence: HIGH
What changedThe company has officially reported meeting its FY26 growth targets and has raised its forward-looking revenue guidance for FY27 while detailing a roadmap to ₹1,000 Cr revenue by FY29.
Why it mattersThe transition toward specialized products like biologics and oncology, coupled with improved working capital management, indicates a structural shift toward higher-margin, regulated market business.
FY26 Revenue: ₹503 CrFY26 PAT Growth: 69%FY27 Revenue Guidance: >₹700 CrFY29 Revenue Target: >₹1,000 CrEBITDA Margin: 24%Cash Conversion Cycle: 170 days
📅 Short termThe upgraded guidance and strong margin performance are likely to be viewed positively by the market in the coming weeks.
📈 Long termThe company's focus on biologics (mAbs) and complex injectables, alongside expansion into EU and South African markets, provides a structural growth runway for the next 3-5 years.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High debtor days (208 days in FY26)
- Regulatory risk regarding EU GMP audit clearance
- Operational drag from African subsidiary
Key Highlights
FY26 consolidated revenue reached ₹503 Cr, achieving the three-year doubling target from FY23.
Profit After Tax (PAT) grew 69% YoY to ₹67.3 Cr, with PAT margins improving from 10.8% to 13.4%.
FY27 revenue guidance upgraded to >₹700 Cr, representing a ~40% growth target over FY26.
Cash conversion cycle improved to 170 days in FY26 from 208 days in FY25.
First biologic (Erythropoietin) achieved successful pre-clinical outcomes, targeting a CY2027 launch.
👀 What to Watch
Monitor the execution of the upgraded FY27 revenue guidance and the outcome of EU GMP audits for the General and Beta Lactam units, which are critical for high-regulated market entry.
Kwality Pharma FY26 Revenue Hits ₹503 Cr; FY27 Guidance Raised to >₹700 Cr
Kwality Pharmaceuticals successfully met its three-year target of doubling revenue, reaching ₹503 crore in FY26 (up 36% YoY). Profitability outpaced revenue growth, with PAT rising 69% to ₹67.3 crore and EBITDA margins expanding 200 bps to 24%. Management has upgraded its FY27 revenue guidance to over ₹700 crore (previously ₹650 crore) and set a long-term target of ₹1,000 crore by FY29. The company is pivoting toward complex injectables and biologics, with its first biologic launch (Kwalipoietin) slated for CY2027.
Confidence: HIGH
What changedThe company has officially reported meeting its FY26 growth targets and has proactively raised its forward-looking revenue guidance for FY27.
Why it mattersThe shift from simple generics to complex biologics and oncology products, combined with a raised guidance, signals management's confidence in sustaining high-margin growth and entering regulated markets like the EU.
FY26 Revenue: ₹503 crFY27 Revenue Guidance: >₹700 crFY26 PAT Growth: 69%EBITDA Margin: 24%Debtor Days: 208 daysFY29 Revenue Target: >₹1,000 cr
📅 Short termThe guidance upgrade and margin expansion are likely to be viewed positively by the market in the coming weeks as they validate the company's growth trajectory.
📈 Long termThe transition to a biologics-led portfolio and expansion into regulated markets (EU/South Africa) provides a structural growth runway toward the ₹1,000 crore revenue goal by FY29.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High debtor days (208) due to geopolitical supply chain disruptions
- Regulatory risk regarding pending EU GMP audits
- Geographic operational drag from the Africa subsidiary
Key Highlights
FY26 consolidated revenue reached ₹503 crore, achieving the 3-year doubling target from ₹250 crore in FY23.
FY27 revenue guidance upgraded to >₹700 crore, representing a ~39% growth target over FY26.
PAT grew 69% YoY to ₹67.3 crore, with PAT margins improving from 10.8% to 13.4%.
Cash conversion cycle improved to 170 days from 208 days, despite elevated debtor days of 208 due to Middle East conflicts.
Initiated bioequivalence programs for 40+ oral solid molecules and development of 3 new monoclonal antibodies (mAbs).
👀 What to Watch
Investors should monitor the successful completion of EU GMP audits for the General and Beta Lactam units, which is a prerequisite for entering high-regulated markets. Additionally, track the clinical progress of the lead biologic 'Kwalipoietin' ahead of its planned CY2027 launch.
CDSCO Nod for Preclinical Pilot Batches of Pembrolizumab Biologic
Kwality Pharmaceuticals has received CDSCO approval to initiate pilot-scale manufacturing of Pembrolizumab for preclinical studies, marking its transition from R&D to the Pre-Clinical stage. This move targets the high-value oncology segment, with the company aiming to be among the first generic entrants post-patent expiry. Given the company's TTM revenue of ₹502 Cr and a healthy OPM of 23.5%, this development aligns with its strategy to pivot from price-sensitive generics to high-margin biologics. Investors should note that while this is a significant milestone, the product is still in the early stages of the regulatory lifecycle.
Confidence: HIGH
What changedThe company has moved from the laboratory research phase to the pilot manufacturing phase for a biosimilar version of the blockbuster oncology drug Pembrolizumab.
Why it mattersSuccessful development of complex biologics like Pembrolizumab represents a structural shift toward high-barrier, high-margin oncology products, which could significantly re-rate the business compared to standard generics.
TTM Revenue: ₹502 CrOperating Profit Margin: 23.5%Market Cap: ₹2784 CrPromoter Holding: 54.87%
📅 Short termThe announcement validates the company's R&D capabilities in the biologics space and is likely to support positive sentiment in the near term.
📈 Long termIf successful, this could lead to a major revenue stream post-patent expiry; however, biologics have long gestation periods and high regulatory hurdles.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- High R&D failure risk in biologics
- Long regulatory gestation period
- Execution risk in scaling complex manufacturing
Key Highlights
Received CDSCO permission on July 24, 2026, to manufacture pilot batches for preclinical studies
Product transitioned from Research and Development (R&D) stage to Pre-Clinical stage
Targeting 'first wave' generic launch of Pembrolizumab following reference product patent expiry
Company reported TTM revenue of ₹502 Cr and TTM PAT of ₹67 Cr as of the announcement date
👀 What to Watch
Monitor the timeline for completion of preclinical studies and the subsequent filing for Phase I/III clinical trials with the CDSCO.
